These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 9516862)
1. Clinical relevance of CD44 cell surface expression and MYCN gene amplification in neuroblastoma. Combaret V; Gross N; Lasset C; Frappaz D; Beretta-Brognara C; Philip T; Beck D; Favrot MC Eur J Cancer; 1997 Oct; 33(12):2101-5. PubMed ID: 9516862 [TBL] [Abstract][Full Text] [Related]
2. Correlation of MYCN amplification, Trk-A and CD44 expression with clinical stage in 250 patients with neuroblastoma. Kramer K; Cheung NK; Gerald WL; LaQuaglia M; Kushner BH; LeClerc JM; LeSauter L; Saragovi HU Eur J Cancer; 1997 Oct; 33(12):2098-100. PubMed ID: 9516861 [TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas. Combaret V; Gross N; Lasset C; Frappaz D; Peruisseau G; Philip T; Beck D; Favrot MC J Clin Oncol; 1996 Jan; 14(1):25-34. PubMed ID: 8558206 [TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of TRKA expression on neuroblastoma: comparison with N-MYC amplification and CD44 expression. Combaret V; Gross N; Lasset C; Balmas K; Bouvier R; Frappaz D; Beretta-Brognara C; Philip T; Favrot MC; Coll JL Br J Cancer; 1997; 75(8):1151-5. PubMed ID: 9099963 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of CD44 prognostic value in neuroblastoma: comparison with the other prognostic factors. Combaret V; Lasset C; Frappaz D; Bouvier R; Thiesse P; Rebillard AC; Philip T; Favrot MC Eur J Cancer; 1995; 31A(4):545-9. PubMed ID: 7576964 [TBL] [Abstract][Full Text] [Related]
6. CD44 expression and modulation on human neuroblastoma tumours and cell lines. Gross N; Beck D; Beretta C; Jackson D; Perruisseau G Eur J Cancer; 1995; 31A(4):471-5. PubMed ID: 7576948 [TBL] [Abstract][Full Text] [Related]
7. Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma. Christiansen H; Sahin K; Berthold F; Hero B; Terpe HJ; Lampert F Eur J Cancer; 1995; 31A(4):541-4. PubMed ID: 7576963 [TBL] [Abstract][Full Text] [Related]
8. [Study on MYCN gene amplification and CD44 expression in neuroblastoma]. Hu HL; He LJ Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318 [TBL] [Abstract][Full Text] [Related]
9. The current contribution of molecular factors to risk estimation in neuroblastoma patients. Berthold F; Sahin K; Hero B; Christiansen H; Gehring M; Harms D; Horz S; Lampert F; Schwab M; Terpe J Eur J Cancer; 1997 Oct; 33(12):2092-7. PubMed ID: 9516860 [TBL] [Abstract][Full Text] [Related]
10. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification. Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322 [TBL] [Abstract][Full Text] [Related]
11. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children. Tonini GP; Boni L; Pession A; Rogers D; Iolascon A; Basso G; Cordero di Montezemolo L; Casale F; Pession A; Perri P; Mazzocco K; Scaruffi P; Lo Cunsolo C; Marchese N; Milanaccio C; Conte M; Bruzzi P; De Bernardi B J Clin Oncol; 1997 Jan; 15(1):85-93. PubMed ID: 8996128 [TBL] [Abstract][Full Text] [Related]
12. MYCN protein expression as a predictor of neuroblastoma prognosis. Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553 [TBL] [Abstract][Full Text] [Related]
13. Relationship between histopathological features, MYCN amplification, and prognosis: a UKCCSG study. United Kingdom Children Cancer Study Group. George RE; Variend S; Cullinane C; Cotterill SJ; McGuckin AG; Ellershaw C; Lunec J; Pearson AD; Med Pediatr Oncol; 2001 Jan; 36(1):169-76. PubMed ID: 11464876 [TBL] [Abstract][Full Text] [Related]
14. MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification. Spitz R; Hero B; Skowron M; Ernestus K; Berthold F Eur J Cancer; 2004 Dec; 40(18):2753-9. PubMed ID: 15571958 [TBL] [Abstract][Full Text] [Related]
15. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. Cohn SL; London WB; Huang D; Katzenstein HM; Salwen HR; Reinhart T; Madafiglio J; Marshall GM; Norris MD; Haber M J Clin Oncol; 2000 Nov; 18(21):3604-13. PubMed ID: 11054433 [TBL] [Abstract][Full Text] [Related]
16. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154 [TBL] [Abstract][Full Text] [Related]
17. Analysis of candidate gene co-amplification with MYCN in neuroblastoma. George RE; Kenyon R; McGuckin AG; Kohl N; Kogner P; Christiansen H; Pearson AD; Lunec J Eur J Cancer; 1997 Oct; 33(12):2037-42. PubMed ID: 9516849 [TBL] [Abstract][Full Text] [Related]
18. CD44 expression in neuroblastoma and related tumors. Comito MA; Savell VH; Cohen MB J Pediatr Hematol Oncol; 1997; 19(4):292-6. PubMed ID: 9256826 [TBL] [Abstract][Full Text] [Related]
19. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification. Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595 [TBL] [Abstract][Full Text] [Related]
20. Loss of chromosome 1p may have a prognostic value in localised neuroblastoma: results of the French NBL 90 Study. Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique (SFOP). Rubie H; Delattre O; Hartmann O; Combaret V; Michon J; Bénard J; Peyroulet MC; Plantaz D; Coze C; Chastagner P; Baranzelli MC; Frappaz D; Lemerle J; Sommelet D Eur J Cancer; 1997 Oct; 33(12):1917-22. PubMed ID: 9516824 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]